Clinical Trial Update: Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update for a sequential CAR-T cell therapy targeting BCMA and GPRC5D in relapsed/refractory multiple myeloma (Phase 1/2, recruiting).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Sequential BCMA/GPRC5D-targeted CAR-T cells

Snippet

Sponsor: Essen Biotech | Conditions: Multiple Myeloma, Multiple Myeloma in Relapse | Phase 1, Phase 2 | Status: RECRUITING